Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Merck Sharp & Dohme Corp.
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
MK-5172 in Combination with MK-8742 in Treatment-Naïve Subjects
•To evaluate the efficacy of MK-5172 in combination with MK-8742 as assessed by the proportion of subjects in the immediate treatment arm achieving SVR12 (Sustained Virologic Response 12 weeks after t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX ? 23) and Prevnar 13? (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older Estudio multicéntrico y doble ciego de la seguridad, tolerabilidad e inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con una vacuna antineumocócica de polisacáridos (PNEUMOVAX?23) y Prevenar 13? (vacuna antineumocócica conjugada 13 valente [proteína diftérica CRM197]) en adultos sanos de 50 años o más de edad
1.-To demonstrate that the safety profile of a single dose of V114 is acceptable. 2.-To compare serotype-specific IgG geometric mean concentrations (GMCs), as measured by Merck?s pneumococcal elect...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Extension to the Odanacatib Fracture Trial (PN018)
(1) to assess long-term changes from baseline in total hip bone mineral density (BMD) after 10 years of treatment with odanacatib 50 mg once-weekly in postmenopausal osteoporotic women previously trea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
MK-5172 in Combination with MK-8742 with and without Ribavirin (RBV) in HCV patients who failed Prior pegylated interferon (peg-IFN) and RBV treatment
1. To evaluate the efficacy of MK-5172 in combination with MK-8742 as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy),...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck)
MAJ Il y a 4 ans
MK-0431A XR in Pediatric Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformain
In pediatric subjects with inadequate control on metformin therapy, after 20 weeks: 1. To asses)s the effect of the addition of sitagliptin (MK-0431A XR) compared with the addition of placebo on A1C ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 Infection
•To compare MK-5172A to SOF/PR in the treatment of HCV, as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co
MAJ Il y a 4 ans
MK-5172/MK-8742 in HCV G1, 4, 6 with Inherited Blood Disorders
•To evaluate the efficacy of MK-5172A as assessed by the proportion of subjects in the immediate treatment arm achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
Japanese Children & Adolescents New Onset Fever & Neutropenia
To evaluate the safety and tolerability of caspofungin in Japanese pediatric patients.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma (rrMM)
1. Compare the Progression Free Survival (PFS) as assessed by CAC blinded central review according to the International Myeloma Working Group response criteria, (IMWG criteria) between treatment arms....
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
MAJ Il y a 4 ans
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients with Homozygous Familial Hypercholesterolemia (HoFH)
In adults with HoFH on a stable dose of their regular medications, we wish to evaluate the effects of adding anacetrapib 100 mg for 12 weeks relative to placebo on plasma concentrations of bad cholest...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
11
Suivant